BAKER BROS. ADVISORS LP
Q2 2021 13F-HR Holdings
Net value change ($000)
-295,425
(-1.3%)
New positions
6
Sold out positions
15
Turnover %
3.7%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2021
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| Seagen Inc. | 901,852 | 13.7% |
| INCY | 93,235 | 3.6% |
| Verve Therapeutics, Inc. | 85,346 | NEW |
| APLS | 71,753 | 99.9% |
| BCRX | 71,689 | 55.5% |
| LEGN | 64,974 | 1936.6% |
| BMRN | 60,183 | 10.5% |
| VSTM | 45,433 | 108.1% |
| JBIO | 32,614 | NEW |
| HRTX | 29,030 | 29.9% |
Top Reduces (Value $000, Stocks/ETFs)
| ALXN | -610,617 | -100.0% |
| KOD | -259,025 | -16.5% |
| Invitae Corp | -256,092 | -42.6% |
| PRLD | -148,820 | -33.9% |
| ABCL | -124,984 | -35.2% |
| ACAD | -59,094 | -5.5% |
| ONC | -57,061 | -1.4% |
| AMARIN CORP PLC | -48,410 | -29.5% |
| ChemoCentryx, Inc. | -33,650 | -100.0% |
| MDGL | -29,325 | -16.7% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|